EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma

Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, Moon Gyeong Yoon, Geum Ok Baek, Minji Kang, Se Ha Jang, Won Park, Yunjin Go, Jestlin Tianthing Ng, Suk Woo Nam, Jee-Yeong Jeong und 6 weitere

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.1038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Hyung Seok Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, Kosin University, Busan, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC recurrence and evaluate the efficiency of GULP PTB domain-containing engulfment adaptor 1 (GULP1) as a predictive and diagnostic marker and therapeutic target for HCC.

Methods

We analyzed genomic datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases via least absolute shrinkage and selection operator Cox regression and 10-fold cross-validation, leading to the development of a 15-gene risk score model, which was validated using three independent datasets. Serum GULP1 and α-fetoprotein levels were assessed to determine the diagnostic accuracy of the model. Using clinical cohorts and patient sera, GULP1 roles were examined, and functional assays in vitro and in vivo were used to evaluate its effects on cell growth, epithelial–mesenchymal transition (EMT), ADP-ribosylation factor 6 (ARF6) activation, and β-catenin signaling.

Results

Our newly developed risk-score model accurately predicted recurrent HCC in all datasets. Among the 15 genes in the risk score model, GULP1 was overexpressed in patients with HCC and independently predicted HCC recurrence. Its expression modulation influenced cell growth and EMT, with observed effects on ARF6 activation and β-catenin signaling pathways.

Conclusions

GULP1 is a crucial biomarker for HCC, serving as a non-invasive diagnostic and predictive tool. It also plays key roles in HCC progression. Our findings highlight the potential use of GULP1 in treatment strategies targeting EMT and HCC recurrence to improve the personalized care and patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorAdaptor Proteins, Signal TransducingHumansMaleFemaleEpithelial-Mesenchymal TransitionCell Line, Tumorbeta CateninADP-Ribosylation FactorsMiddle Agedalpha-FetoproteinsNeoplasm Recurrence, LocalAnimalsPrognosisGene Expression Regulation, NeoplasticCell ProliferationMice

Stichwörter der Autor:innen

DiagnosisGULP PTB domain-containing engulfment adaptor 1Liver cancerMetastasisRecurrence

Substanzen

Biomarkers, Tumorbeta CateninADP-Ribosylation Factorsalpha-FetoproteinsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Biochemistry, College of Medicine, Kosin University, Busan, Korea.
  • Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
  • Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
  • Department of Bioscience and Biotechnology, Graduate School, Chungnam National University, Daejeon, Korea.
  • Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Suwon, Korea.

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare
  • National Research Foundation of Korea
  • Commercialization Promotion Agency
  • Ministry of Science and ICT

Zitieren

APA

Kim, H. S., Yoon, J. H., Choi, J. Y., Yoon, M. G., Baek, G. O., Kang, M., Jang, S. H., Park, W., Go, Y., Ng, J. T., Nam, S. W., Jeong, J. Y., Han, J. E., Cho, H. J., Lim, S. B., Kim, S. S., Cheong, J. Y., & Eun, J. W. (2025). GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.1038

Vancouver

Kim HS, Yoon JH, Choi JY, Yoon MG, Baek GO, Kang M, et al. GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.1038

BibTeX
@article{Kim2025,
  author = {Kim, Hyung Seok and Yoon, Jung Hwan and Choi, Ji Yi and Yoon, Moon Gyeong and Baek, Geum Ok and Kang, Minji and Jang, Se Ha and Park, Won and Go, Yunjin and Ng, Jestlin Tianthing and Nam, Suk Woo and Jeong, Jee-Yeong and Han, Ji Eun and Cho, Hyo Jung and Lim, Su Bin and Kim, Soon Sun and Cheong, Jae Youn and Eun, Jung Woo},
  title = {GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.1038}
}
Kostenlos starten →